Diabetes: KOL Insight

Maximum Purchase:
1 unit
Publication Date:
December 2013
Latest Update Bulletin:
November 2014
PDF, 216 Pages
Adding to cart… The item has been added

Therapy Trends KOL Insight: Diabetes analyses the current and predicted key issues, current products and late-stage pipeline product and gives you qualitative information based on exclusive interviews with 12 key opinion leaders (KOLs) who are leading clinicians working in diabetes in the US and Europe.

Their views on specific drugs and treatment pathways provide a unique front line perspective from those working in clinical setting. The results of these detailed and extensive interviews are incorporated though out the text so they can be read in the context of the issue or product being discussed.

While barriers to entry remain high with added scrutiny over cardiovascular and other safety risks, evident by Tresiba’s (insulin degludec; Novo Nordisk) recent US failure, the exponential market growth makes diabetes one of the most attractive opportunities in Pharma.

With the number of unmet needs in diabetes treatment and management, KOLs note that companies that can address these needs and differentiate their products from existing players will see significant traction in this lucrative indication. In addition, therapies showing significant incremental advances also have potential to usurp market share from the gold standard treatments.

Key Benefits

  • Comprehend the current trends driving and shaping the global diabetes market
  • Understand the future landscape and how new drug classes will fit into the treatment algorithm
  • Compare and contrast the clinical profile of the insulins, DPP-IV, GLP-1 and SGLT-2 classes and assess their competitive strengths and weaknesses
  • Assess the commercial and clinical potential of the next generation pipeline drugs, biosimilars, and existing therapies.
  • Appreciate KOL calls for novel therapies and understand the commercial threat and opportunity for current products.
  • Develop positioning strategies based on KOL insight
  • Identify critical areas of unmet clinical need and opportunities for better disease management
  • Evaluate the performance of companies with the most robust new product pipelines
  • Recognise the key factors KOLs predict will drive future treatment trends
  • Access to Regular Update Bulletins: expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.
    • The August 2014 update includes information on Toujeo, Eli Lilly/Boehringer Ingelheim’s Abasria, Novo Nordisk’s Xultophy/IDegLira, peglispro

Answers to Critical Questions

  • How might new therapies impact on the current first-line treatments?
  • What are the current unmet needs and major challenges in diabetes treatment?
  • What are the most promising late-stage classes in development?
  • Which therapies are KOLs eagerly awaiting?
  • How will the new therapies be positioned against each other in each of the disease segments?
  • In what ways could players improve on existing therapies and what impact could this have on prescribing?
  • How will treatment of diabetes look in the future?
  • How do KOLs think the pricing environment is shaping the uptake of new diabetes treatments?
  • What clinical research trends do KOLs predict for future diabetes therapies

KOL Panel

North America

  • Dr Elif Oral, MD, Associate Professor of Endocrinology, University of Michigan, Ann Arbor, MI.
  • Dr Sonal Singh, MD, MPH, Assistant Professor, Division of General Internal Medicines, John Hopkins University, Baltimore, MD.
  • Dr Carol Wysham, MD, Clinical Associate Professor of Medicine, Division of General Internal Medicines, University of Washington School of Medicine, Washington.
  • Dr Joel Zonszein, MD, Director of the Clinical Diabetes Center at the University Hospital Albert Einstein College of Medicine, a Division of Montefiori Medical Center, NY.
  • Requested anonymous, Associate Professor of Medicine, Endocrinology and Metabolism, Duke University, Durham, NC.


  • Professor Bernard Charbonnel, MD, Professor of Endocrinology and Metabolic Diseases, University of Nantes; Head of the Internal Medicine, Endocrinology and Diabetes Department, Hôtel Dieu, University Hospital of Nantes, France.
  • Professor Melanie Davies, MD, Honorary Consultant, Diabetes, University Hospital Leicester, Leicestershire, UK.
  • Professor Marc Donath, MD, Director, Endocrinology, Diabetes and Clinical Nutrition, University Hospital, Basel, Switzerland.
  • Professor Jens Holst, MD, Professor of Medical Physiology, Department of Biomedical Sciences; Director of the Research Cluster for Diabetes and Obesity; Vice Chairman, Faculty of Health Sciences, University of Copenhagen, Denmark.
  • Professor John Wilding, MD, Head of the Department of Obesity and Endocrinology, University of Liverpool, UK.
  • 2 Anonymous German Key Opinion Leaders

Key Topics Covered

Current diabetes marketplace Current marketed therapies
Epidemiology Pipeline therapies
Aetiology Unmet needs
Diagnosis Current treatment algorithm
Current treatment landscape Future treatment algorithm
Reimbursement of key diabetes brands Future developments in Diabetes


Also Available: Consensus Outlook

Therapy Trends Consensus Outlook: Diabetes is an in-depth forecast report based on consensus figures from 13 leading analysts. Rich in tables and charts, the report maps the impact of future events to predict product and company performance. In addition, gain access to an interactive forecast data analysis spreadsheet comparing critical market parameters including market size, product sales, market shares and competitive status over the period 2007 to 2017. Learn more

To purchase the KOL Insight and Consensus Outlook module, click here.


This report provides a qualitative overview of the current and future diabetes market. Information was gathered from telephone interviews held with twelve key opinion leaders (KOLs), from across the major diabetes markets, including France, Germany, Italy, the UK and the US. These regions were selected because they contain many of the largest global markets for the pharmaceutical industry, and also influence the dynamics of Pharma markets in other countries.

KOL selection is based on clinical experience, scientific publications, involvement with Pharma, involvement in clinical trials and record of presenting at high profile international conferences.

Subjects covered in the interviews included future diagnostic and therapeutic strategies for diabetes, the future of diabetes drug classes, and new drugs entering the market. These leading KOLs also gave their views on current research, the usefulness of existing diabetes drug classes, the cost of newer drugs and other concerns in the therapy area.

Update Bulletins Offer Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord’s guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

  • Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.
  • Your Therapy Trends Report purchase includes access to Update Bulletins once published.